KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Income towards Parent Company: 2012-2024

Historic Income towards Parent Company for Xenon Pharmaceuticals (XENE) over the last 13 years, with Dec 2024 value amounting to -$248.2 million.

  • Xenon Pharmaceuticals' Income towards Parent Company fell 44.76% to -$90.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$320.2 million, marking a year-over-year decrease of 50.05%. This contributed to the annual value of -$248.2 million for FY2024, which is 36.07% down from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Income towards Parent Company stood at -$248.2 million for FY2024, which was down 36.07% from -$182.4 million recorded in FY2023.
  • Xenon Pharmaceuticals' Income towards Parent Company's 5-year high stood at -$28.8 million during FY2020, with a 5-year trough of -$248.2 million in FY2024.
  • In the last 3 years, Xenon Pharmaceuticals' Income towards Parent Company had a median value of -$182.4 million in 2023 and averaged -$185.3 million.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Income towards Parent Company soared by 30.67% in 2020, and later tumbled by 173.54% in 2021.
  • Xenon Pharmaceuticals' Income towards Parent Company (Yearly) stood at -$28.8 million in 2020, then plummeted by 173.54% to -$78.9 million in 2021, then crashed by 58.99% to -$125.4 million in 2022, then crashed by 45.43% to -$182.4 million in 2023, then slumped by 36.07% to -$248.2 million in 2024.